1
|
Cortellini A, Parisi A, Cannita K, Venditti O, Pavese F, D'Orazio C, Lanfiuti Baldi P, Vicentini V, Vicentini R, Porzio G, Verna L, Ficorella C. Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
2
|
Di Iorio B, Cirillo M, Bellizzi V, Stellato D, De Santo NG, Aquino A, Anastasio P, Barchiesi S, Bonanno D, Buccino A, Cappabianca F, Cesaro A, Cestaro R, Chiuchiolo L, Chiuchiolo L, Ciaccia L, Cicchella T, Cillo N, Cioffi M, Cirillo E, Confessore N, Costanzo R, D'Apice L, De Felice E, Delgado G, De Luca M, De Luca P, De Luna V, De Maio A, De Pascale C, Della Volpe L, De Simone V, De Simone W, Di Benedetto A, Di Costanzo L, Di Donato R, Di Serafino A, Fabozzi GM, Fiorentino P, Fragetta G, Fumante M, Galise A, Giangrande C, Giobbe A, Gnasso A, Granato P, Guastaferro P, Iacono G, Iandolo R, Iengo G, Lamberti C, La Verde A, Liccardo D, Maddalena L, Mancini L, Manfreda L, Mari R, Marinelli G, Marinelli G, Martignetti V, Mascolini N, Maurodopoulos C, Migliorati M, Memoli M, Milone A, Milone D, Monaco G, Monteleone E, Natale G, Oggero AR, Pavese F, Petrelli P, Pizzola AR, Raucci B, Rubino R, Salvati G, Santoro D, Saviano C, Savignano M, Sforza C, Spitali L, Staulo P, Stellato D, Taddeo U, Terracciano V, Tomasino G, Tramontano P, Veniero P, Ventre M, Verrillo E, Violante B, Vitiello P, Viola G. Prevalence and Correlates of Anemia and Uncontrolled Anemia in Chronic Hemodialysis Patients – The Campania Dialysis Registry. Int J Artif Organs 2018. [DOI: 10.1177/039139880703000408] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background This study investigated prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients. Methods A cross-sectional analysis was performed on registry data for 2,746 chronic (<6 months) hemodialysis patients aged 25–84. Data collection included years of dialysis, hours of dialysis/wk, disease causing hemodialysis, body mass index (BMI), erythropoietin (EPO) treatment, hemoglobin, markers of viral hepatitis, serum albumin, calcium, and phosphorus. Results Prevalence was 88.7% for anemia (hemoglobin <11 g/100 mL and EPO treatment at any Hb level), 39.4% for uncontrolled anemia (hemoglobin<11 g/100 mL). Gender, years of dialysis, hereditary cystic kidney disease (HCKD), and low BMI (<24 kg/m2) were independent correlates of anemia (P<0.001). Gender, HCKD, low BMI, serum albumin and calcium were independent correlates of uncontrolled anemia (P<0.05). An interaction was found between age (not correlated with anemia and uncontrolled anemia) and the association of gender with uncontrolled anemia (P<0.05). EPO doses were higher in patients with high prevalence of uncontrolled anemia than in patients with low prevalence (i.e., women vs men, other diseases vs HCKD, low vs not-low BMI, P<0.01). Gender, years of dialysis, HCKD, BMI, serum albumin, and calcium were independent correlates of the hemoglobin/EPO dose ratio in patients on EPO treatment (P<0.05). Conclusion Anemia and uncontrolled anemia are more frequent in hemodialysis patients with short-term dialysis, diseases other than HCKD, low BMI, and female gender. Gender effect was lower in elderly patients. Uncontrolled anemia was also associated with low serum albumin and calcium, suggesting that these parameters are indices of EPO resistance.
Collapse
Affiliation(s)
- B. Di Iorio
- Department of Nephrology, Second University of Naples, Naples - Italy
- Department of Nephrology, Solofra Hospital, Solofra - Italy
| | - M. Cirillo
- Department of Nephrology, Second University of Naples, Naples - Italy
| | - V. Bellizzi
- Department of Nephrology, Solofra Hospital, Solofra - Italy
| | - D. Stellato
- Department of Nephrology, Second University of Naples, Naples - Italy
| | - N. G. De Santo
- Department of Nephrology, Second University of Naples, Naples - Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
The Guide to the expression of uncertainty in measurement (GUM) requires, “that the results of a measurement have been corrected for all recognised significant systematic effects and that every effort has been made to identify such effects”, before the issue of evaluating their uncertainty is tackled. In addition, the GUM also requires that a model is used, expressing the functional dependence of the measurand on identified input quantities. The paper discusses the inter-relations between the so-defined two sets of influence quantities and proposes to unify their treatment.
Collapse
|
4
|
Pavese F. Rounding, stipulation and notation issues in measurement. Int J Metrol Qual Eng 2013. [DOI: 10.1051/ijmqe/2012036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
In the context of measurement and of the definition of measurement units, a problem well known in computing science, the inherent propagation and accumulation of rounding errors throughout the intermediate steps of numerical calculation, is discussed in this paper, with some issues in notation, namely of integer numbers.
Collapse
|
6
|
Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407-11. [PMID: 11216954 DOI: 10.1016/s0735-1097(00)01158-x] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVES The aim of this study was to investigate in dialysis patients with symptomatic heart failure New York Heart Association (NYHA) functional class II or III whether the addition of carvedilol to conventional therapy is associated with beneficial effects on cardiac architecture, function and clinical status. BACKGROUND Congestive heart failure (CHF) in chronic hemodialyzed patients, particularly when associated with dilated cardiomyopathy, represents an ominous complication and is an independent risk factor for cardiac mortality. METHODS We enrolled 114 dialysis patients with dilated cardiomyopathy. All patients were treated with carvedilol for 12 months in a double-blind, placebo-controlled, randomized trial. The patients underwent M-mode and two-dimensional echocardiography at baseline, 1, 6 and 12 months after the randomization. Each patient's clinical status was assessed using an NYHA functional classification that was determined after 6 and 12 months of treatment. RESULTS Carvedilol treatment improved left ventricular (LV) function. In the active-treatment group, the increase in LV ejection fraction (from 26.3% to 34.8%, p < 0.05 vs. basal and placebo group) and the reduction of both LV end-diastolic volume (from 100 ml/m2 to 94 ml/m2, p < 0.05 vs. basal and placebo group) and end-systolic volume (from 74 ml/m2 to 62 ml/m2, p < 0.05 vs. basal and placebo group) reached statistical significance after six months of therapy, compared with baseline and corresponding placebo values, and they remained constant at one year of treatment (p < 0.05 vs. basal and placebo group). The clinical status of patients, assessed by NYHA functional classification, improved during the treatment period. Moreover, at the end of the trial, there were no patients in NYHA functional class IV in the carvedilol group, compared with 5.9% of the patients in the placebo arm. CONCLUSIONS One year of therapy with carvedilol in dialysis patients with CHF and dilated cardiomyopathy reduces LV volumes and improves LV function and clinical status.
Collapse
Affiliation(s)
- G Cice
- Institute of Cardiovascular Clinic and Surgery, Division of Cardiology, Second University of Naples, Italy.
| | | | | | | | | | | | | |
Collapse
|